SISD 2021 POSTERS
TOP 3 POSTER
#100 - Disease Characteristics and Burden in Patients With Atopic Dermatitis: Insights From Two Phase 3 Studies of Ruxolitinib Cream

Eric L. Simpson, MD, MCR, Mark Lee, MD, Kanwaljit K. Brar, MD, Michael E. Kuligowski, MD, PhD, MBA, May E. Venturanza, MD, Kang Sun, PhD, Darryl Toth, MD
#101 - Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials

Mark Lebwohl, Linda Stein Gold, Bruce Strober, Kim Papp, April Armstrong, Jerry Bagel, Leon Kircik, Benjamin Ehst, H. Chih-ho Hong, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, Anna M. Tallm
#102 - Selective Inhibition of Tyrosine Kinase 2 (TYK2) With Deucravacitinib Compared With Janus Kinase (JAK) 1–3 Inhibitors

Anjaneya Chimalakonda, PhD, James Burke, PhD, Lihong Cheng, MS, Ian Catlett, PhD, Aditya Patel, MD, MBA, Jun Shen, PhD, Ihab G. Girgis, PhD, Subhashis Banerjee, MD, John Throup, PhD
#103 - Deucravacitinib, an Oral, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, Reduces Psoriasis Area and Severity Index (PASI) Component Scores Across Body Regions in Patients With Plaque Psoriasis​

Alan Menter, MD, Andrew Blauvelt, MD, Bruce Strober, MD, PhD, Matthew J. Colombo, PhD, Renata M. Kisa, MD, Sudeep Kundu, PhD, Subhashis Banerjee, MD, Craig Leonardi, MD
#104 - Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Moderate to Severe Plaque Psoriasis

Bruce Strober, MD, PhD, Alice B. Gottlieb, MD, PhD, Diamant Thaçi, MD, Luis Puig, MD, PhD, Matthew J. Colombo, PhD, Sudeep Kundu, PhD, Renata Kisa, MD, Subhashis Banerjee, MD
#105 - 5-year Efficacy of Tildrakizumab 100 and 200 mg in Achieving and Maintaining PASI 75/90/100 and PGA 0/1 in reSURFACE 1 and 2

Andrew Blauvelt, Aaron S. Farberg, Rodney Sinclair, Sameh Hanna, Akihiko Asahina, Atsuyuki Igarashi, Scott Guenthner, Kimberly Eads, Heather Roebuck, Alan M Mendelsohn, Stephen J Rozzo, Lyn Guenther
#106 - Safety of Tildrakizumab 100 mg and 200 mg through 5 years of Exposure in reSURFACE 1 and reSURFACE 2

George Han, MD, PhD, Pablo Fernández-Peñas, MD, PhD, Lorne Albrecht, MD, Akihiko Asahina, MD, PhD, Atsuyuki Igarashi, MD, PhD, Andrea Nguyen, PA-C, MS, Wendy Cantrell, DNP, CRNP, Jayme Heim, MSN, FNP-BC, Alan M Mendelsohn, MD, Stephen J Rozzo, PhD, Neal Bhatia, MD
#107 - Real-world Data Analysis of Dose Escalation and Associated Costs in Biologic Treatment of Psoriasis

Jerry Bagel, MD, Brad Glick, DO, MPH, FAOCD, Jashin J. Wu, MD, FAAD, Xue Song, PhD, Ishveen Chopra, PhD, Matthew Brouillette, MPH, Alan Mendelsohn, MD, Stephen Rozzo, PhD, George Han, MD, PhD
#108 - Analysis of Reddit Reveals Atopic Dermatitis Patient Questions

Alana Kurtti, BS; Jared Jagdeo, MD, MS
TOP 3 POSTER
#109 - Non-invasive Transcriptome Extraction using the Mindera Dermal Biomarker Patch

Tobin J. Dickerson, PhD, Eric Andrade, BS, Byung-In Lee, PhD, Yipeng Wang, MD, PhD, Bradford J. Taft, PhD, and Thejus Mannath, MS
TOP 3 POSTER
#110 - Association between Biologic Therapy and COVID-19 Infection Risk in Patients with Psoriasis

Jashin J. Wu, MD, Jeffrey Liu, Akshitha Thatiparthi, Amylee Martin, Edmond Malka
#111 - A challenging Case of a Chronic, Relapsing Bullous Dermatosis with Negative Serologic Tests Treated Successfully with Dapsone 

Leah Shin BA, Lulu Wong MD, Harry Dao MD. 
#112 - Methotrexate Therapy during the COVID-19 Pandemic is Not a Reason for Concern

Zainab A. Jafri, D.O., Shikha Walia, B.S., Mirjana G. Ivanic B.A., Jashin J. Wu, M.D.
#113 - Rapid Itch Improvement in Children With Severe Atopic Dermatitis Treated With Dupilumab: A Phase 3 Subset Analysis

Gil Yosipovitch, MD; Jonathan I. Silverberg, MD; Jashin J. Wu, MD; Zhen Chen, PhD; Randy Prescilla, MD; Ana B. Rossi, MD; Dimittri Delevry, PharmD
#114 - Adverse Food Reactions and Their Role in Atopic Dermatitis

Andrea M. Rustad, Melissa A. Nickles, Peter A. Lio
#115 - A Case of Acral Lichen Sclerosus et Atrophicus

Haley D. Heibel, MD, Angela R. Styles, MD, and Clay J. Cockerell, MD, MBA
#116 - An Overview of Therapies for Scalp Dermatomyositis

Avani Kolla, BPhil; Lynn Liu, BS; Katharina Shaw, MD; Jerry Shapiro, MD; Alisa Femia, MD; Kristen Lo Sicco, MD, FAAD
#117 - Tralokinumab Prevents Flares in Moderate-to-Severe Atopic Dermatitis: Post Hoc Analyses of a Randomized Phase 3 Clinical Trial (ECZTRA 3)

Jonathan I. Silverberg, MD, PhD, MPH, Sebastien Barbarot, MD, PhD, Julia Welzel, MD, Mahreen Ameen, MD, Jacob P. Thyssen, MD, PhD, DMSci, Mark Lomaga, MD, PhD, Christina Kurre Olsen, MSc, PhD, Thomas Mark, MSc, Karen Veverka, PhD, Joshua Corriveau, PharmD, MBA, Joseph F. Merola, MD, MMSc, FAAD, FACR
#118 - Progressive and Sustained Improvements in the Extent and Severity of Atopic Dermatitis in Patients with Moderate-to-severe Disease Treated with Tralokinumab in Combination with Topical Corticosteroids as Needed

Andrew F. Alexis, MD, MPH, Matthew Zirwas, MD, Andreas Pinter, MD, David N. Adam, MD, FRCPC, Andrea Chiricozzi, MD, Andrew E. Pink, MD, Thomas Mark, MSc, Ann-Marie Tindberg, MSc, Karen Veverka, PhD, Jonathan I. Silverberg, MD, PhD, MPH
#119 - Early and Sustained Improvements in Patient-Reported Outcomes with Tralokinumab Plus Topical Corticosteroids as Needed in Moderate-to-Severe Atopic Dermatitis

Boni E. Elewski, MD, Sonja Ständer, MD, Matthew Zirwas, MD, Juan Francisco Silvestre, MD, Sunil Kalia, MD, MHSc, FAAD, FRCPC, Jan Gutermuth, MD, PhD, Thomas Mark, MSc, Ann-Marie Tindberg, MSc, Karen Veverka, PhD, Jonathan I. Silverberg, MD, PhD, MPH
#120 - Impact of Targeting Interleukin-13 on Staphylococcus Aureus Colonization: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Tralokinumab in Adult Patients with Atopic Dermatitis

Thomas Bieber, MD, PhD, MDRA, Lisa A Beck, MD, Andrew Pink, MD, Hidehisa Saeki, MD, PhD, Lawrence Eichenfield, MD, Thomas Werfel, MD, Anders Rosholm, MSc, Mads Røepke, MSc, Karen Veverka, PhD, Amy Paller, MD
#121 - Early-Onset Cutaneous Pseudolymphoma Secondary to Influenza Vaccination in Skin of Color

Eric L. Simpson, MD, MCR, Mark Lee, MD, Kanwaljit K. Brar, MD, Michael E. Kuligowski, MD, PhD, MBA, May E. Venturanza, MD, Kang Sun, PhD, Darryl Toth, MD
#122 - Bullous Pemphigoid: Readability and Quality of Online Health Resources  

Terri Shih BS, Natalie M. Villa MD, Vivian Y. Shi MD, Jennifer L. Hsiao MD
#123 - Characterization of Dermatomyositis and its Associated Comorbidities in a Predominantly Black and Hispanic Population

Tracy Ngo BS, Junwen Deng BA, Dean Hosgood Ph.D., Tagai Musaev MD, Emily Hejazi MD, Alana Deutsch BA, Holly Kanavy DO
#124 - Dermatitis in Stringed Instrumentalists

Henry Lim, Marshall Hall M.P.H., Sajid Surve D.O.
#125 - Association between Psoriasis and Asthma Among US adults in the 2009-2014 NHANES

Amylee Martin, B.S., Akshitha Thatiparthi, B.S., Jeffrey Liu, B.S., Shaokui Ge, Ph.D., Alexander Egeberg, M.D., Ph.D., Jashin J. Wu, M.D.
#126 - YouTube Videos as Source of Patient Information for Atopic Dermatitis Topical Therapies

Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD 
#127 - Bibliometric analysis of hidradenitis suppurativa publication trends from Asia and Australasia

Devea R. De, Alyssa M. Thompson, Justine Seivright, Swetha Atluri, Amanda Ederle, Anna Swigert, Joanna A. Jaros, Jennifer L. Hsiao, Vivian Y. Shi
#128 - Unusual Gingival Erythema and Swelling

Scarlet Charmelo-Silva, DDS , Alhanouf Bin Dakhil
#129 - Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

L Stein Gold; MG Lebwohl; KA Papp; MJ Gooderham; LH Kircik; ZD Draelos; SE Kempers; DM Pariser; J Alonso-Llamazares; DP Toth; Kathleen Smith; RC Higham; L Navale; H Welgus; DR Berk
#130 - Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Symptom Burden in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

LH Kircik; MG Lebwohl; KA Papp; MJ Gooderham; L Stein Gold; ZD Draelos; SE Kempers; SK Tyring; LE Albrecht; M Wiseman; LK Ferris; K Smith; RC Higham; L Navale; H Welgus; DR Berk
#131 - The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study

MJ Gooderham, LH Kircik, M Zirwas, M Lee, SE Kempers, ZD Draelos, LK Ferris, TM Jones, E Saint-Cyr Proulx, R Bissonnette, N Bhatia, ST Guenthner, RA Koppel, H Welgus, C Merritt, M Elias, L Navale, RC Higham, M Droege, DR Berk
#132 - Psoriasis on Social Media: Analysis of Content, Authorship and Accuracy  

Morgan Nguyen BA, Ellen Wu BA, Slaton Case BA, Ahmad Amin MD
#133 - Adverse Effects of Face Masks and Implications from COVID-19

Akshitha Thatiparthi, B.S., Jeffrey Liu, B.S., Amylee Martin, B.S., Jashin J. Wu, M.D.
#134 - Provider evaluation and patient experience among patients with genital psoriasis

Pavane L. Gorrepati, Gideon P. Smith